Rodriguez-Galindo Carlos, Friedrich Paola, Alcasabas Patricia, Antillon Federico, Banavali Shripad, Castillo Luis, Israels Trijn, Jeha Sima, Harif Mhammed, Sullivan Michael J, Quah Thuan Chong, Patte Catherine, Pui Ching-Hon, Barr Ronald, Gross Thomas
Carlos Rodriguez-Galindo and Paola Friedrich, Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA; Patricia Alcasabas, Philippines General Hospital, Manila, Philippines; Federico Antillon, Unidad Nacional de Oncología Pediátrica, and Francisco Marroquín Medical School, Guatemala City, Guatemala; Shripad Banavali, Tata Memorial Hospital, Mumbai, India; Luis Castillo, Hospital Pereira Rossell, Montevideo, Uruguay; Trijn Israels, Vrije Universiteit Medical Center, Amsterdam, the Netherlands; Sima Jeha and Ching-Hon Pui, St Jude Children's Research Hospital, Memphis, TN; Mhammed Harif, Centre Hospitalier Universitaire Mohammed VI, Marrakech, Morocco; Michael J. Sullivan, Royal Children's Hospital, Melbourne, Australia; Thuan Chong Quah, National University Health System, Singapore; Catherine Patte, Institute Gustave-Roussy, Villejuif, France; Ronald Barr, McMaster University and McMaster Children's Hospital, Hamilton, ON, Canada; and Thomas Gross, National Cancer Institute Center for Global Health, Bethesda, MD.
J Clin Oncol. 2015 Sep 20;33(27):3065-73. doi: 10.1200/JCO.2014.60.6376. Epub 2015 Aug 24.
Advances in the treatment of childhood cancers have resulted in part from the development of national and international collaborative initiatives that have defined biologic determinants and generated risk-adapted therapies that maximize cure while minimizing acute and long-term effects. Currently, more than 80% of children with cancer who are treated with modern multidisciplinary treatments in developed countries are cured; however, of the approximately 160,000 children and adolescents who are diagnosed with cancer every year worldwide, 80% live in low- and middle-income countries (LMICs), where access to quality care is limited and chances of cure are low. In addition, the disease burden is not fully known because of the lack of population-based cancer registries in low-resource countries. Regional and ethnic variations in the incidence of the different childhood cancers suggest unique interactions between genetic and environmental factors that could provide opportunities for etiologic research. Regional collaborative initiatives have been developed in Central and South America and the Caribbean, Africa, the Middle East, Asia, and Oceania. These initiatives integrate regional capacity building, education of health care providers, implementation of intensity-graduated treatments, and establishment of research programs that are adjusted to local capacity and local needs. Together, the existing consortia and regional networks operating in LMICs have the potential to reach out to almost 60% of all children with cancer worldwide. In summary, childhood cancer burden has been shifted toward LMICs and, for that reason, global initiatives directed at pediatric cancer care and control are needed. Regional networks aiming to build capacity while incorporating research on epidemiology, health services, and outcomes should be supported.
儿童癌症治疗方面的进展部分得益于国家和国际合作倡议的发展,这些倡议明确了生物学决定因素,并产生了风险适应性疗法,在使急性和长期影响最小化的同时最大限度地提高治愈率。目前,在发达国家接受现代多学科治疗的儿童癌症患者中,超过80%被治愈;然而,在全球每年约16万名被诊断患有癌症的儿童和青少年中,80%生活在低收入和中等收入国家(LMICs),在这些国家,获得优质医疗服务的机会有限,治愈的可能性较低。此外,由于资源匮乏国家缺乏基于人群的癌症登记处,疾病负担尚未完全明了。不同儿童癌症发病率的区域和种族差异表明,遗传和环境因素之间存在独特的相互作用,这可能为病因学研究提供机会。中美洲、南美洲、加勒比地区、非洲、中东、亚洲和大洋洲已经开展了区域合作倡议。这些倡议整合了区域能力建设、医疗保健提供者的教育、实施强度分级治疗以及建立根据当地能力和当地需求调整的研究项目。总之,儿童癌症负担已向低收入和中等收入国家转移,因此,需要针对儿童癌症护理和控制的全球倡议。旨在建设能力同时纳入流行病学、卫生服务和结果研究的区域网络应得到支持。